An Exploratory Clinical Study of Autologous Anti-CD20/CD30 Chimeric Antigen Receptor T Cells (anti-CD20/CD30 CAR-T Cells) in Subjects with Relapsed/Refractory Lymphoma
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Anti CD20/CD30 chimeric antigen receptor T cell therapy Shanghai First Song Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Shanghai First Song Biotechnology
- 08 Aug 2024 New trial record